Intercept to Announce First Quarter 2022 Financial Results on May 6, 2022
Intercept Pharmaceuticals (Nasdaq: ICPT) will report its first quarter 2022 financial results before market opening on May 6, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq: ICPT) will report its first quarter 2022 financial results before market opening on May 6, 2022. The announcement will be followed by a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the conference call on the company's investor webpage or by calling a designated toll-free number. Intercept focuses on innovative treatments for progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
Positive
- Upcoming announcement of Q1 2022 financial results may provide insights into company performance.
Negative
- None.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was +1.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISTOWN, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2022 financial results prior to market open on Friday, May 6, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.
The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free) with passcode 7738727. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept:
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002, Intercept has operations in the United States, Europe, and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
Contact:
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.